Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04797611 · ClinicalTrials.gov registry record · NA
STEM-Parkinson's Disease
A NA study of Parkinson Disease and Parkinson's Disease and Parkinsonism, sponsored by Scion NeuroStim.
- Completed
- Registry status
- NA
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT04797611: Completed NA study of Parkinson Disease and Parkinson's Disease and Parkinsonism, sponsored by Scion NeuroStim.
NCT04797611 is a NA study of Parkinson Disease and Parkinson's Disease and Parkinsonism that has completed, run by Scion NeuroStim. The registered enrollment target is 188 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04797611, a NA study of Parkinson Disease and Parkinson's Disease and Parkinsonism, has completed, sponsored by Scion NeuroStim.
- COMPLETED
- Registry status
- NA
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a double-blinded, controlled, and randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
Primary Outcome
The MDS-NMS is a 52-item rater-administered scale used to assess a wide range of non-motor symptoms in Parkinson's disease. It measures both frequency (0/never to 4/ \>51% of the time) and severity (0/not present to 4/major distress or disturbance) of 13 domains (depression, anxiety, apathy, psychosis, impulse control/related disorders, cognition, orthostatic hypotension, urinary, sexual, gastrointestinal, sleep/wakefulness, pain, and other). Each question is scored by multiplying frequency x se
Conditions Studied
Interventions
- DEVICE TNM Device
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- Headlands Research Orlando - Orlando
- USF Parkinson's Disease and Movement Disorders Center - Tampa
Michigan
- Quest Research - Farmington Hills
- Mercy Health Saint Mary's - Grand Rapids
Pennsylvania
- Thomas Jefferson University - Philadelphia
- University of Pennsylvania - Philadelphia
Texas
- Texas Movement Disorder Specialist - Georgetown
- Houston Methodist Neurological Institute - Houston
Arizona
- Movement Disorder Center of Arizona - Scottsdale
California
- Cedars-Sinai Medical Center - Los Angeles
Colorado
- CenExel Rocky Mountain Clinical Research - Englewood
Kansas
- University of Kansas Medical Center - Parkinson's Disease Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2022-05-19 |
| Est. Completion | 2024-12-06 |
| Phase | NA |
What the finished NCT04797611 record still lists
NCT04797611 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which TNM Device is the first listed.
NCT04797611 names 20 study sites across 15 states, led by Florida, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04797611 about?
NCT04797611 is a clinical study titled "STEM-Parkinson's Disease". This is a double-blinded, controlled, and randomized clinical trial (RCT) to establish the safety and efficacy of a non-invasive neuromodulation device for treating symptoms associated with Parkinson's disease.
What is the current status of trial NCT04797611?
This trial is currently completed. It is a NA study. The enrollment target is 188 participants. The study started on 2022-05-19. Estimated completion is 2024-12-06.
What conditions does trial NCT04797611 study?
This clinical trial studies the following conditions: Parkinson Disease, Parkinson's Disease and Parkinsonism.
What interventions are being tested in trial NCT04797611?
The interventions under investigation include: TNM Device (DEVICE).
Who is sponsoring clinical trial NCT04797611?
This trial is sponsored by Scion NeuroStim, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04797611 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04797611's enrollment target sits among peer trials
188 51st of 297 higher than 247 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI